Literature DB >> 3815075

Development of tolerance to respiratory depression in morphine- and etorphine-pellet-implanted mice.

S C Roerig, J M Fujimoto, D G Lange.   

Abstract

Tolerance to opiate-induced depression of respiratory rate was studied in unanesthetized mice following chronic treatment with morphine or etorphine. Mice implanted subcutaneously (s.c.) with morphine pellets showed development of tolerance to morphine administered both s.c. and intracerebroventricularly (i.c.v.) and to s.c. etorphine and heroin. However, no cross-tolerance to i.c.v. etorphine or heroin was observed. In contrast, mice implanted with etorphine pellets demonstrated development of tolerance to all 3 agents given either s.c. or i.c.v. These findings on development of tolerance to opiate-induced respiratory depression differ from our previous studies measuring analgesia in which mice tolerant to s.c. morphine did not demonstrate development of tolerance to s.c. etorphine or heroin (unidirectional non-cross-tolerance). To investigate a possible mechanism for this difference in development of tolerance, apparent pA2 values for respiratory rate depression were determined for s.c. morphine-naloxone and etorphine-naloxone. The apparent pA2 values for these two opiates were similar, in contrast to the dissimilar apparent pA2 values previously found when analgesia was measured. The apparent pA2 values demonstrated differences between the respiratory depressant and analgesic effects of these opiates, but there was no obvious relationship between apparent pA2 values and the absence of unidirectional non-cross-tolerance observed for respiratory depression.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3815075     DOI: 10.1016/0006-8993(87)90627-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

1.  Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner.

Authors:  S Tai; W S Hyatt; C Gu; L N Franks; T Vasiljevik; L K Brents; P L Prather; W E Fantegrossi
Journal:  Pharmacol Res       Date:  2015-09-08       Impact factor: 7.658

2.  Tolerance and sensitization to chronic escalating dose heroin following extended withdrawal in Fischer rats: possible role of mu-opioid receptors.

Authors:  Katharine M Seip-Cammack; Brian Reed; Yong Zhang; Ann Ho; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2012-07-25       Impact factor: 4.530

3.  Low-dose morphine elicits ventilatory excitant and depressant responses in conscious rats: Role of peripheral μ-opioid receptors.

Authors:  Fraser Henderson; Walter J May; Ryan B Gruber; Alex P Young; Lisa A Palmer; Benjamin Gaston; Stephen J Lewis
Journal:  Open J Mol Integr Physiol       Date:  2013-08-01

4.  Co-activation of μ- and δ-opioid receptors elicits tolerance to morphine-induced ventilatory depression via generation of peroxynitrite.

Authors:  Alex P Young; Ryan B Gruber; Joe F Discala; Walter J May; Dylan McLaughlin; Lisa A Palmer; Stephen J Lewis
Journal:  Respir Physiol Neurobiol       Date:  2013-03-05       Impact factor: 1.931

5.  Discriminative stimulus effects of midazolam and abecarnil in rats treated chronically with diazepam or abecarnil.

Authors:  D A Lytle; M W Emmett-Oglesby; D N Stephens
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

6.  Potentiation of acute opioid-induced respiratory depression and reversal of tolerance by the calcium antagonist nimodipine in awake rats.

Authors:  F Ruiz; M Dierssen; J Flórez; M A Hurlé
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-12       Impact factor: 3.000

7.  Role of protein kinase C and mu-opioid receptor (MOPr) desensitization in tolerance to morphine in rat locus coeruleus neurons.

Authors:  C P Bailey; J Llorente; B H Gabra; F L Smith; W L Dewey; E Kelly; G Henderson
Journal:  Eur J Neurosci       Date:  2009-01       Impact factor: 3.386

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.